



Medi-Cal Rx

Commercial JYNNEOS® Vaccine Reimbursement

October 15, 2024

Background

On April 1, 2024, Bavarian Nordic commercially launched the JYNNEOS® vaccine, identified by the 11-digit NDCs 50632000101 and 50632000103. Claims submitted for these NDCs with a date of service (DOS) on or after April 1, 2024, are a covered Medi-Cal Rx benefit. Note that NDC 50632000101 is an inner pack without a price on file; pharmacies should either submit with NDC 50632000103 or submit a paper claim when dispensing NDC 50632000101, making sure to include the “outer” NDC in the remarks area of the claim form. For more information on how to submit a paper claim, refer to the *Missing Price* section of the [Medi-Cal Rx Provider Manual](#).

What Pharmacy Providers Need to Know

Effective for claims submitted with a DOS on or after April 1, 2024, Medi-Cal Rx will reimburse pharmacy providers for commercial JYNNEOS vaccine claims submitted with NDC 50632000103 utilizing the following standard vaccine payment methodology:

Ingredient Cost + Dispensing Fee + Administration Fee

JYNNEOS is U.S. Food and Drug Administration (FDA)-approved for members 18 years of age and older and is a Vaccines For Children (VFC)-funded vaccine. Claims submitted by VFC-enrolled providers for the VFC-funded vaccine when administered to eligible Medi-Cal members will not be reimbursed for the ingredient cost.

In addition, claims submitted to Medi-Cal Rx for the government-supplied JYNNEOS vaccine (NDC 50632000102) will not be reimbursed for the ingredient cost.

Medi-Cal Rx is aware that claims submitted on or after September 13, 2024, for commercial vaccine NDC 50632000103 were only reimbursed for the administration fee. This has been corrected effective for claims submitted on or after October 11, 2024. Refer to the alert published on October 4, 2024: [Coming Soon: Commercial JYNNEOS® Vaccine Reimbursement Correction](#).

What Pharmacy Providers Need to Do

For claims submitted with a DOS on or after April 1, 2024, no additional action is required by pharmacy providers at this time. For claims submitted with a DOS on or after this policy is implemented, pharmacy providers should submit claims to Medi-Cal Rx as follows:

1. Use the 11-digit NDC of the commercially launched JYNNEOS vaccine.
 - **Note:** Medi-Cal Rx encourages pharmacy providers to use NDC 50632000103 when submitting claims.
2. Include the following Drug Use Review (DUR) code values to receive reimbursement of the administration fee:
 - Reason for Service Code (NCPDP field 439-E4): PH – Preventive Health Care
 - Professional Service Code (NCPDP field 440-E5): MA – Medication Administration
 - Result of Service Code (NCPDP field 441-E6): 3N – Medication Administration

Resources

- [Vaccines For Children Program: Medi-Cal Reference Guide](#)
- [Vaccines For Children Program Policy and Billing Guidance for Pharmacy Providers](#)
- [Medi-Cal Reimbursement of Vaccines For Children \(VFC\)-Enrolled Pharmacy Providers and for VFC and Non-VFC Vaccines – Frequently Asked Questions \(FAQs\)](#)
- [JYNNEOS Vaccine Commercial Transition](#)

Contact Information

You can call the Medi-Cal Rx Customer Service Center (CSC) at 1-800-977-2273, which is available 24 hours a day, 7 days a week, 365 days per year.

For other questions, email Medi-Cal Rx Education & Outreach at MediCalRxEducationOutreach@primetherapeutics.com.